Content
Frontiers of Medicine >> 2022, Volume 16, Issue 5 doi: 10.1007/s11684-021-0902-1
Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors
Abstract
Keywords
benefit ; China ; eligibility ; immune checkpoint inhibitor ; public health
Content